Cantor Fitzgerald Reiterates Neutral on Karuna Therapeutics, Maintains $330 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan reiterated a Neutral rating on Karuna Therapeutics (NASDAQ:KRTX) and maintained a $330 price target.
February 20, 2024 | 5:38 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cantor Fitzgerald analyst Charles Duncan reiterated a Neutral rating on Karuna Therapeutics and maintained a $330 price target.
The reiteration of a Neutral rating and maintenance of a $330 price target by a reputable analyst suggests stability in the analyst's outlook towards Karuna Therapeutics. This stability is likely to have a neutral short-term impact on the stock as it does not introduce new positive or negative expectations.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100